BSE · 523620
Phaarmasia Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹25 Cr with net profit ₹-2 Cr — a -6.33% net margin, versus -1.66% the period before.
Shareholding
As of 2026-06-30
- Promoter73.51%
- Public26.43%
- DII0.06%
20,286 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 5.07× from low to high.
Risk flags
Derived from disclosed data
- 52-week range spans 5.07× (₹26 to ₹131.75) — an unusually wide band.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #75 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 176.1 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 88.75 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 19.67 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,246 Cr | 88.01 | 18.16 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,837 Cr | 545.38 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
| Phaarmasia Ltd.(this company) | ₹61 Cr | 30.88 | 3.41 | 8.93% | 37.25% |
AI analysis
AI-generated · google/gemini-2.5-flashPhaarmasia Ltd. is listed with a market capitalization of Rs 64 Cr. The company reported a revenue of Rs 25.12 Cr and a profit margin of 37.25%. The earnings per share (EPS) stands at Rs 2.89. The 52-week high for the share price was Rs 131.75, and the 52-week low was Rs 26.
Positives
- +The debt-to-equity ratio is low at 0.01.
- +The promoter holding is substantial at 73.5134% as of March 2026.
- +There are no reported promoter share pledges.
Negatives
- −The company has reported negative annual net profits for the past four years, including a net loss of Rs -1.5894 Cr in March 2025.
- −Annual EPS has been negative for the past four fiscal years, reaching -2.33 in March 2025.
- −Quarterly net profit was negative at Rs -0.7 Cr in March 2026.
- −The number of shareholders decreased from 22146 in June 2016 to 20301 in March 2026.
Financial Performance
Phaarmasia Ltd. reported annual revenue of Rs 25.1151 Cr in March 2025. The company's net profits have been negative in recent annual periods, with a net loss of Rs -1.5894 Cr in March 2025. Quarterly performance shows a net profit of Rs 16.27 Cr in December 2025 on a revenue of Rs 16.05 Cr, but a net loss of Rs -0.7 Cr in March 2026 on a revenue of Rs 7.73 Cr.
Profitability & Returns
The company's profit margin is 37.25%. Return on equity (ROE) is 8.93% and return on capital employed (ROCE) is 11.2899%. The earnings per share (EPS) for the latest available period is Rs 2.89, however, annual EPS has been negative for the past four years, reaching -2.33 in March 2025.
Balance Sheet
Phaarmasia Ltd. maintains a low debt-to-equity ratio of 0.01. The book value per share is Rs 26.15. No dividend yield was reported.
Ownership & Pledges
Promoter holding stands at 73.5134% as of March 2026. There are no reported promoter share pledges. The number of shareholders was 20301 as of March 2026, down from 22146 in June 2016.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.